Örüm Mehmet Hamdi, Kapıcı Yaşar, Sönmez Doğancan, Tanrıkulu Ali Baran, Gümüşay Merve, Koçhan Onur, Örüm Dilek, Hocaoğlu Çiçek
Elazığ Mental Health and Diseases Hospital, Psychiatry, Elazığ, 23200, Turkey.
Department of Psychiatry, Faculty of Medicine, Adıyaman University, Adıyaman, Turkey.
BMC Health Serv Res. 2025 Jan 4;25(1):20. doi: 10.1186/s12913-024-12134-1.
Many variables may affect approaches of psychiatrists to methamphetamine-associated psychotic disorder (MAP) treatment. This study was aimed to reach adult psychiatrists actively practicing in Turkey through an internet-based survey and to determine their practices and attitudes to MAP treatment.
In this internet-based study, participants were divided into three groups based on their answers: Those who do not follow-up any MAP patient were group 1 (n = 78), partially involved in the treatment process of at least one patient diagnosed with MAP were group 2 (n = 128), completely involved in the treatment process of at least one patient diagnosed with MAP were group 3 (n = 202).
Psychotropic preferences in insomnia (p < 0.001), typical oral antipsychotic choice (p < 0.001), preferred doses of olanzapine/risperidone/aripiprazole/amisulpride for maintenance treatment (p < 0.001), long-acting injectable antipsychotic use practices (p < 0.001), non-antipsychotic psychotropic use characteristics (p < 0.001), extrapyramidal system side effect experiences (p < 0.001), delirium and life-threatening situations encounter rates (p < 0.001) were significantly different between group 2 and group 3. While the duration of maintenance with antipsychotics in the first MAP episode was similar between group 2 and group 3 (p = 0.254), it was different in the second and subsequent MAP episodes (p < 0.05). A binary logistic regression model containing the experiences of long-acting injectable antipsychotic use, extrapyramidal system side effect, and delirium was created (overall p < 0.001, Nagelkerke R = 0.435; Hosmer and Lemeshow test p = 0.203).
This first study in the field, which examines the current issue in detail, reveals that there are many factors that seriously affect psychiatrists' approaches to MAP treatment in Turkey.
This study was approved by the Ethics Committee of the Fırat University (Date: 14/09/2023; Number: 2023/12-12).
许多变量可能会影响精神科医生对甲基苯丙胺所致精神障碍（MAP）治疗的方法。本研究旨在通过一项基于互联网的调查，联系在土耳其积极执业的成年精神科医生，并确定他们对MAP治疗的实践和态度。
在这项基于互联网的研究中，参与者根据其回答被分为三组：未随访任何MAP患者的为第1组（n = 78），部分参与至少一名诊断为MAP患者治疗过程的为第2组（n = 128），完全参与至少一名诊断为MAP患者治疗过程的为第3组（n = 202）。
第2组和第3组在失眠时的精神药物偏好（p < 0.001）、典型口服抗精神病药物选择（p < 0.001）、奥氮平/利培酮/阿立哌唑/氨磺必利维持治疗的首选剂量（p < 0.001）、长效注射用抗精神病药物使用情况（p < 0.001）、非抗精神病精神药物使用特征（p < 0.001）、锥体外系副作用经历（p < 0.001）、谵妄和危及生命情况的发生率（p < 0.001）方面存在显著差异。虽然第2组和第3组在首次MAP发作时抗精神病药物维持治疗的持续时间相似（p = 0.254），但在第二次及后续MAP发作时有所不同（p < 0.05）。建立了一个包含长效注射用抗精神病药物使用经历、锥体外系副作用和谵妄经历的二元逻辑回归模型（总体p < 0.001，Nagelkerke R = 0.435；Hosmer和Lemeshow检验p = 0.203）。
该领域的第一项详细研究当前问题的研究表明，在土耳其有许多因素严重影响精神科医生对MAP治疗的方法。
本研究经菲拉特大学伦理委员会批准（日期：2023年9月14日；编号：2023/12 - 12）。
